Nephrology Flashcards
(200 cards)
- How is neonatal AKI classified and staged?
Classification: Modified KDIGO staging
- Based on serum creatinine rise and urine output reduction
- What are the key differences between prerenal, intrinsic, and postrenal AKI?
Prerenal: Decreased perfusion (FeNa <1%)
- Intrinsic: Tubular or glomerular damage (FeNa >2%)
- Postrenal: Obstruction (hydronephrosis on imaging)
- What are the key laboratory findings in prerenal AKI?
Findings: BUN:Cr ratio >20:1, low urine sodium (<20), high urine osmolality, low FeNa (<1%)
- What is the management of neonatal AKI?
Management: Fluid and electrolyte balance, avoid nephrotoxins, diuretics if fluid overload, dialysis if refractory
- What are the stages of AKI based on KDIGO criteria?
KDIGO stages:
Stage 1:
Serum Creatinine: ↑ by ≥0.3 mg/dL within 48 hrs OR 1.5–1.9× baseline
Urine Output: <0.5 mL/kg/h for 6–12 hrs
Stage 2:
Serum Creatinine: 2.0–2.9× baseline
Urine Output: <0.5 mL/kg/h for ≥12 hrs
Stage 3:
Serum Creatinine: ≥3.0× baseline OR ≥4.0 mg/dL OR initiation of renal replacement therapy
Pediatrics: eGFR <35 mL/min/1.73 m²
Urine Output: <0.3 mL/kg/h for ≥24 hrs OR anuria ≥12 hrs
- What is the role of fractional excretion of sodium (FeNa) in AKI evaluation?
FeNa: Helps distinguish types of AKI
- <1% in prerenal, >2% in ATN
- Not reliable if on diuretics
- How is neurogenic bladder managed in pediatric patients?
Management: Clean intermittent catheterization (CIC), anticholinergics, monitor renal function and bladder pressures
- What conditions are associated with abnormal flow curves in uroflowmetry?
Abnormal curves: Plateau (obstruction), staccato (intermittent contraction), interrupted (underactive bladder)
- What is the initial treatment for overactive bladder in children?
Initial treatment: Timed voiding, behavioral therapy, fluid optimization, constipation management
- What pharmacologic agents are used for refractory overactive bladder?
Pharmacologic agents: Oxybutynin, solifenacin, tolterodine (anticholinergics)
- Used after behavioral failure
- What is the role of a bladder and bowel dysfunction (BBD) program in pediatric nephrology?
BBD program: Integrated approach for constipation, voiding dysfunction, and recurrent UTIs
- Improves urinary continence and prevents renal damage
- What are red flags in a child presenting with enuresis?
Red flags: Daytime incontinence, abnormal stream, recurrent UTIs, poor growth, back pain, spinal stigmata
- What is monosymptomatic nocturnal enuresis and how is it treated?
Monosymptomatic: Enuresis without daytime symptoms
- Treat with reassurance, motivational therapy, enuresis alarm, desmopressin if >6 years
- What is the initial evaluation of a child with enuresis?
Evaluation: History, voiding diary, urinalysis, screen for constipation and UTI
- Ultrasound if abnormal exam or daytime symptoms
- How is CKD staged in pediatrics?
Staging (KDIGO):
- G1: ≥90, G2: 60–89, G3a: 45–59, G3b: 30–44, G4: 15–29, G5: <15 mL/min/1.73m²
- How is anemia of CKD managed?
Management: Iron supplementation, erythropoiesis-stimulating agents (ESAs)
- Target Hgb ~11–12 g/dL
- What is the management of mineral bone disease in CKD?
Management: Phosphate binders, active vitamin D analogs (calcitriol), monitor calcium/phosphate/PTH
- What is the role of dietary phosphate restriction in CKD?
Dietary phosphate restriction: Reduces hyperparathyroidism and bone disease
- Limit processed foods and dairy
- What is the impact of growth hormone therapy on renal function in CKD?
GH therapy: Stimulates linear growth in CKD
- No major effect on GFR
- Improves final adult height if started early
- What is the first-line antihypertensive agent in children with proteinuric CKD?
First-line: ACE inhibitors or ARBs
- Reduce proteinuria and delay CKD progression
- What is the definition of chronic kidney disease (CKD) in children?
CKD: Kidney damage or GFR <60 mL/min/1.73m² for ≥3 months
- Includes structural or functional abnormalities
- What vaccinations are recommended in children with CKD?
Recommended: Hepatitis B, pneumococcal, influenza, varicella (live vaccines if not immunosuppressed)
- What are the effects of chronic metabolic acidosis on pediatric bone and growth?
Effects: Impaired growth, rickets, osteopenia
- Due to bone buffering and resistance to GH and IGF-1
- What are the signs of chronic metabolic acidosis in children?
Signs: Poor growth, rickets, bone pain, muscle weakness
- Often seen in chronic RTA or CKD